Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer

• Xiaohong Tan ,

  Contributed equally to this work with: Xiaohong Tan, Julian Carretero

  Affiliations State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Julian Carretero ,

  Contributed equally to this work with: Xiaohong Tan, Julian Carretero

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain

  ⨯
• Zhao Chen,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Jishuai Zhang,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Yanxiao Wang,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Jicheng Chen,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Xiubin Li,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Hui Ye,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Chuanhao Tang,

  Affiliation Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

  ⨯
• Xuan Cheng,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Ning Hou,

  Affiliation State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China

  ⨯
• Xiao Yang ,

  * E-mail: kwong1@partners.org (KKW); yangx@nic.bmi.ac.cn (XY)

  Affiliations State Key Laboratory of Proteomics, Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, China, Model Organism Division, E-institutes of Shanghai Universities, Shanghai JiaoTong University, Shanghai, China

  ⨯
• Kwok-Kin Wong

  * E-mail: kwong1@partners.org (KKW); yangx@nic.bmi.ac.cn (XY)

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, United States of America, Belfer Institute for Applied Cancer Science, Boston, Massachusetts, United States of America

  ⨯